Back to search
FDAFDA · Food and drugs·Recall number D-0149-2024

Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distributed by: Novartis Pharmaceuticals Corp., East Hanover, N.J. 07936, NDC 0078-1077-66

Published December 20, 2023 · Recall initiated: November 20, 2023

Summary

FDA records drug Class III recall D-0149-2024, published December 20, 2023 and initiated November 20, 2023. Recalling firm: Siegfried Barbera, SL; Status: Completed; Reported quantity: 2016; Lot: Lot# ME2713; Exp. 02/2025 Lot # MF8286, ML1860; Exp. 04/2025. Class III means the product is not likely to cause adverse health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated

Get an email if VOTRIENT has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
VOTRIENT
Manufacturer
Siegfried Barbera, SL
Distributor
Nationwide
Lot
Lot# ME2713; Exp. 02/2025 Lot # MF8286, ML1860; Exp. 04/2025
Risk classification
Class III
Area (FDA)
drug
Country
Spain

Related recalls

Questions about this recall

Was Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distributed by: Novartis Pharmaceuticals Corp., East Hanover, N.J. 07936, NDC 0078-1077-66 recalled?

Yes. FDA published recall D-0149-2024 on December 20, 2023. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: VOTRIENT.